AUM Biosciences awarded 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year from Frost & Sullivan

SINGAPORE, April 9, 2019 /PRNewswire/ -- AUM Biosciences has been honored with the 2019 Asia-Pacific Biotech  Entrepreneurial Company of the Year Award from Frost & Sullivan.


Vandana Iyer, Senior Research Analyst, Health & Wellness, TechVision, Frost & Sullivan noted that AUM Biosciences' unique 'Asia to Global' strategy, combined with biomarker-driven precision medicine plans and digitization trials, is ideally poised to address growing industry needs for designing faster and more affordable treatment strategies distinctly for the Asian landscape.


These include the company's integration of 3 key elements in its quest of targeted cancer therapeutics: developing affordable small molecule therapies, adopting "No Biomarker-No Drug" mandate and leveraging digitization for smart data access that improves the patient management journey in a personalized manner.


Frost & Sullivan firmly believes that AUM's drug development strategies have the power to lead a long-overdue paradigm shift in the Asian biotech landscape by facilitating the development of affordable treatment options and enabling improved quality of life for cancer patients.


"Amidst this backdrop, the company's lead MNK inhibitor candidate, AUM001, demonstrates an impressive safety profile and can potentially optimize the current treatment strategies for chronic myeloid leukemia and multiple solid tumors with significant unmet medical needs. AUM's unparalleled, Asia-focused drug development plans are set to enable disruptive biotech transformations in the global small molecule industry," she added.


AUM Biosciences also uniquely addresses the main concerns of the Asian biotech landscape related to treatment availability and affordability by facilitating the development of Asia-focused, affordable treatment strategies that are likely to transform the future of biomarker-based, digital precision medicine approaches.


Frost & Sullivan recognizes that AUM's comprehensive biomarker-based and trial digitization plans are likely to enable significant disruptions within the existing pharma and biotech landscape by enabling the development of precision therapies for the Asia-Pacific region. The company's affordable small molecule therapies of Asian origin will also facilitate improved disease management across the world.


"We are proud to receive this award. AUM is committed towards implementing a Holistic Approach of developing affordable cancer drugs from Asia to Global. This recognition makes our commitment even stronger," said AUM Biosciences CEO, Mr. Vishal Doshi


The recipients of the annual Frost & Sullivan Asia-Pacific Best Practice Awards were identified based on in-depth research conducted by Frost & Sullivan's analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends. The short-listed companies were evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.


About AUM Biosciences


AUM Biosciences (AUM) is an oncology-focused, Singapore HQ biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, we aim to create value for patients, physicians and our partners by harnessing the power of precision medicine, and digital health. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of cancers prevalent in Asians but has the potential to address global market.


AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.


About Frost & Sullivan


Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. 

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies. 










































Contact:




Melissa Tan

Haslinda Sarabaini                           

Corporate Communications – Asia Pacific

AUM Biosciences

P: +65 6890 0926

P: +6568086034

F: +65 6890 0999

E: pr@aumbiosciences.com

E: melissa.tan@frost.com




http://ww2.frost.com 

www.aumbiosciences.com 



                                                                                               

Related Links :

http://www.frost.com

Tags:
Look out for further updates on our Facebook fan page!

Related Articles

  • 【網民職場Talk】下屬奉旨幫上司執手尾?打工仔列慘痛經歷

    打工仔工作繁忙,加上工時長,每天與同事相處的時間比家人、伴侶、朋友還要多,如果不幸遇上能力不高的上司,更會為工作添煩添亂。一個體貼下屬、表現出眾的上司,可謂可遇不可求,當你在職場打滾多年後,或許會發現職位高低往往與能力的高低不成正比。有網民向社交媒體專頁《奴工處》投稿,分享為人下屬的辛酸。

  • 【人才管理】經濟環境轉差取消聚餐 分析企業4個節流方法

    【晴報專訊】本港經濟環境轉差,有網民表示最近知悉公司為節流而取消冬至聚餐,感到無奈。另有網民認為與其舉辦聚餐,不如讓員工放半日假。有人力顧問表示,中小企的管理方式較彈性,部分公司會因應市況而取消聚餐,寧願預留資金應付新年後更嚴峻的經濟環境。

  • 【職場熱話】美企大派聖誕花紅 198名員工分7800萬!

    又到聖誕,又到聖誕……不少打工仔都期待放假輕鬆一下,度過開心聖誕。日前美國馬里蘭州一間房地產公司就大派花紅,將接近8,000萬港元的年終花紅,發放給198名員工,當作他們的聖誕禮物,有不少員工在拿到花紅時更當場落淚。

  • 【政府工略】政府合約僱員將與公務員睇齊 同享17日年假

    【晴報專訊】政府非公務員合約僱員有薪公眾假期,將與公務員看齊。港府向立法會提交文件,透露明年4月1日將予所有合約僱員「加假」5天,各人可享有17天有薪公眾假期。

  • 【職場文化】樂高辦公室斥700萬大變身 茶水間變「蘭桂坊」

    【經濟日報專訊】樂高(LEGO)進駐香港22年,深受大小朋友歡迎。樂高香港辦公室斥資700萬元進行大變身,採用北歐簡約風格設計,同時注入濃厚的香港街道及交通文化特色,打造「小香港」。樂高邀請本港模型家洪子健,以積木拼砌多件辦公室裝飾,當中包括首枝3D自動轉換訊號的紅綠燈。

  • 【企業管理】Burger King 錯誤優惠致蝕錢? 只因一種漢堡

    【經濟日報專訊】Burger King 在美國以經常推出折扣優惠作招徠,但近日該公司最大的加盟商 Carrols Restaurant Group 便因為於 6 月 3 日至 8 月 26 日期間,提供錯誤的優惠,招致約 830 萬美元(約 6,500 萬港元)損失。

  • 【職場人際】上司與下屬如癡男怨女?發生衝突應咁樣做

    【經濟日報專訊】職場上容易產生衝突和糾紛,本地也曾發生不少職場衝突事件,若沒有適當處理,鬧上法庭不免需時又花錢。專家建議,勞資雙方遇到衝突時,考慮以調解形式介入,協助雙方進行適當溝通,尋求解決辦法。

  • 【職場小學問】5個簡單方法 令會議更有效率

    不少辦公室都有著會議文化,每星期開會數次,向上司/老闆匯報工作進度,或與同事Brainstorm刺激思維。然而,員工逗留在會議室的時間愈長,用於銷售、創作和生產的時間就愈少,因此過份冗長或過多的會議,不但影響工作進度,更會打擊士氣。如果你想會議更有效率,可參考以下5個簡單的方法:

  • 【人才管理】新人難教又怕醜 4招有助快速成長

    主管常埋怨新人辦事能力低,沒法承受壓力,而新人則埋怨主管無好好教導,或是怕犯錯給同事添麻煩。雙方不了解對方,成為了惡性循環。作為主管,經驗比新人多,應主動出手了解下屬「為什麼會這樣」。以下就有帶領新人的4個原則,讓主管好好教導新人:

  • 【人才管理】本地公司因應交通 允員工在家工作

    【經濟日報專訊】反修例風波觸發連串示威,有團體計劃周一(9月2日)及周二(9月3日)發起「三罷」,促請政府回應市民訴求。